Skip to main content Accessibility help
×
Home

COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE

  • Anne-Isabelle Poullié (a1), Magali Cognet (a2), Aline Gauthier (a3), Marine Clementz (a3), Sylvain Druais (a3), Hans-Martin Späth (a4), Lionel Perrier (a5), Oliver Scemama (a6), Catherine Rumeau Pichon (a6) and Jean-Luc Harousseau (a6)...

Abstract

Objectives: Untreated obstructive sleep apnea-hypopnea syndrome (OSAHS) is associated with excessive daytime sleepiness, increased risk of cardiovascular (CV) disease, and road traffic accidents (RTAs), which impact survival and health-related quality of life. This study, funded by the French National Authority for Health (HAS), aimed to assess the cost-effectiveness of different treatments (i.e., continuous positive airway pressure [CPAP], dental devices, lifestyle advice, and no treatment) in patients with mild-to-moderate OSAHS in France.

Methods: A Markov model was developed to simulate the progression of two cohorts, stratified by CV risk, over a lifetime horizon. Daytime sleepiness and RTAs were taken into account for all patients while CV events were only considered for patients with high CV risk.

Results: For patients with low CV risk, incremental cost-effectiveness ratio (ICER) of dental devices versus no treatment varied between 32,976 EUR (moderate OSAHS) and 45,579 EUR (mild OSAHS) per quality-adjusted life-year (QALY), and CPAP versus dental devices, above 256,000 EUR/QALY. For patients with high CV risk, CPAP was associated with a gain of 0.62 QALY compared with no treatment, resulting in an ICER of 10,128 EUR/QALY.

Conclusion: The analysis suggests that it is efficient to treat all OSAHS patients with high CV risk with CPAP and that dental devices are more efficient than CPAP for mild-to-moderate OSAHS with low CV risk. However, out-of-pocket costs are currently much higher for dental devices than for CPAP (i.e., 3,326 EUR versus 2,430 EUR) as orthodontic treatment is mainly non-refundable in France.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

Hide All
1. Haute Autorité de Santé. Rapport SAHOS. Evaluation économique. September 2014. http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-09/rapport_sahos_-_evaluation_economique.pdf (accessed October 6, 2014).
2. Société de Pneumologie de Langue Française. Recommendations for clinical practice. Obstructive sleep apnea hypopnea syndrome in adults. Rev Mal Respir. 2010;27:806833.
3. McDaid, C, Griffin, S, Weatherly, H, et al. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: A systematic review and economic analysis. Health Technol Assess. 2009;13:iiixiv, 1.
4. Marin, JM, Carrizo, SJ, Vicente, E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. Lancet. 2005;365:10461053.
5. Buchner, NJ, Sanner, BM, Borgel, J, et al. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med. 2007;176:12741280.
6. Campos-Rodriguez, F, Martinez-Garcia, MA, de la Cruz-Moron, I, et al. Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: A cohort study. Ann Intern Med. 2012;156:115122.
7. Weatherly, HL, Griffin, SC, Mc Daid, C, et al. An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. Int J Technol Assess Health Care. 2009;25:2634.
8. Haute Autorité de, Santé. Choices in methods for economic evaluation. Saint-Denis, France: Haute Autorité de Santé; October 2012.
9. Thomasouli, MA, Brady, EM, Davies, MJ, et al. The impact of diet and lifestyle management strategies for obstructive sleep apnoea in adults: A systematic review and meta-analysis of randomised controlled trials. Sleep Breath. 2013;17:925935.
10. Observatoire national interministériel de sécurité routière. La sécurité routière en France. Bilan de l'année 2011. Paris La Défense: Documentation Française; 2011.
11. Philip, P, Sagaspe, P, Lagarde, E, et al. Sleep disorders and accidental risk in a large group of regular registered highway drivers. Sleep Med. 2010;11:973979.
12. INSERM. Crude death rates per 100,000 population, France (mainland), 2010 http://www.cepidc.inserm.fr/cgi-bin/broker.exe (accessed September 2, 2013).
13. Currie, CJ, McEwan, P, Peters, JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): Descriptive analysis from the first 20,000 subjects. Value Health. 2005;8:581590.
14. Lindgren, P, Kahan, T, Poulter, N, et al. Utility loss and indirect costs following cardio-vascular events in hypertensive patients: The ASCOT health economic substudy. Eur J Health Econ. 2007;8:2530.
15. Sadatsafavi, M, Marra, CA, Ayas, NT, et al. Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea-hypopnoea. Sleep Breath. 2009;13:241252.
16. Commissariat général à la stratégie et à la perspective. L’évaluation socio-économique des investissements publics. Tome 1. Paris: CGSP; 2013.
17. Tuppin, P, Alexandre, R, Drouin, J, et al. Cout annuel pour l'assurance maladie de la prise en charge des AVC en France en 2011 d'après les données du système national d'information inter-régimes d'assurance maladie (SNIIRAM). Dans: 18e journée de la société française neuro-vasculaire. 20–22 novembre 2013, Paris: Maison International; 2013.
18. Anandam, A, Patil, M, Akinnusi, M, et al. Cardio-vascular mortality in obstructive sleep apnea treated with continuous positive airway pressure or oral appliance: An observational study. Respirology. 2013;18:1184–90.
19. Fava, C, Dorigoni, S, Dalle Vedove, F, et al. Effect of continuous positive airway pressure (CPAP) on blood pressure in patients with obstructive sleep apnea/hypopnea. A systematic review and meta-analysis. Chest. 2014;145:762771.
20. Second European Stroke Prevention Study. ESPS-2 Working Group. J Neurol. 1992;239:299301.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed